Lexeo Therapeutics Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
59
- Stock Symbol
-
LXEO
- Investments
-
2
- Share Price
-
$2.96
- (As of Friday Closing)
Lexeo Therapeutics General Information
Description
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
Contact Information
Website
www.lexeotx.comCorporate Office
- 345 Park Avenue South
- 6th Floor
- New York, NY 10010
- United States
Corporate Office
- 345 Park Avenue South
- 6th Floor
- New York, NY 10010
- United States
Lexeo Therapeutics Timeline
Lexeo Therapeutics Stock Performance
As of 20-Nov-2026, Lexeo Therapeutics’s stock price is $2.96. Its current market cap is $245M with 82.8M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.96 | $2.95 | $2.55 - $10.99 | $245M | 82.8M | 1.96M | -$1.26 |
Lexeo Therapeutics Financials Summary
As of 30-Sep-2026, Lexeo Therapeutics has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 72,566 | 610,457 | 71,033 | 523,375 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (111,658) | (103,806) | (103,773) | (67,213) |
| Net Income | (105,282) | (99,961) | (98,333) | (66,394) |
| Total Assets | 243,916 | 268,688 | 146,942 | 139,807 |
| Total Debt | 6,247 | 7,886 | 9,924 | 11,638 |
Lexeo Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Lexeo Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Lexeo Therapeutics Comparisons
Industry
Financing
Details
Lexeo Therapeutics Competitors (20)
One of Lexeo Therapeutics’s 20 competitors is Solid Biosciences, a Formerly VC-backed company based in Charlestown, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Solid Biosciences | Formerly VC-backed | Charlestown, MA | ||||
| Tenaya Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Intellia Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Prime Medicine | Formerly VC-backed | Cambridge, MA | ||||
| Taysha Gene Therapies | Formerly VC-backed | Dallas, TX |
Lexeo Therapeutics Patents
Lexeo Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023215308-A1 | Methods and pharmaceutical compositions for the treatment and the prevention of cardiomyopathy associated with friedreich ataxia | Pending | 01-Feb-2022 | ||
| EP-4472674-A1 | Methods and pharmaceutical compositions for the treatment and the prevention of cardiomyopathy associated with friedreich ataxia | Pending | 01-Feb-2022 | ||
| US-20250161483-A1 | Methods and pharmaceutical compositions for the treatment and the prevention of cardiomyopathy associated with friedreich ataxia | Pending | 01-Feb-2022 | ||
| WO-2023150563-A1 | Methods and pharmaceutical compositions for the treatment and the prevention of cardiomyopathy associated with friedreich ataxia | Inactive | 01-Feb-2022 | A61K48/0033 |
Lexeo Therapeutics Signals
Lexeo Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Lexeo Therapeutics Acquisitions (2)
Lexeo Therapeutics’s most recent deal was a Merger/Acquisition with Mantle Therapeutics for . The deal was made on 23-Sep-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Mantle Therapeutics | 23-Sep-2026 | Merger/Acquisition | Drug Discovery | ||
| Stelios Therapeutics | 16-Jul-2021 | Merger/Acquisition | Drug Discovery |
Lexeo Therapeutics ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
35.62 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,593
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Lexeo Therapeutics FAQs
-
When was Lexeo Therapeutics founded?
Lexeo Therapeutics was founded in 2018.
-
Where is Lexeo Therapeutics headquartered?
Lexeo Therapeutics is headquartered in New York, NY.
-
What is the size of Lexeo Therapeutics?
Lexeo Therapeutics has 59 total employees.
-
What industry is Lexeo Therapeutics in?
Lexeo Therapeutics’s primary industry is Drug Discovery.
-
Is Lexeo Therapeutics a private or public company?
Lexeo Therapeutics is a Public company.
-
What is Lexeo Therapeutics’s stock symbol?
The ticker symbol for Lexeo Therapeutics is LXEO.
-
What is the current stock price of Lexeo Therapeutics?
As of 20-Nov-2026 the stock price of Lexeo Therapeutics is $2.96.
-
What is the current market cap of Lexeo Therapeutics?
The current market capitalization of Lexeo Therapeutics is $245M.
-
Who are Lexeo Therapeutics’s competitors?
Solid Biosciences, Tenaya Therapeutics, Intellia Therapeutics, Prime Medicine, and Taysha Gene Therapies are some of the 20 competitors of Lexeo Therapeutics.
-
What is Lexeo Therapeutics’s annual earnings per share (EPS)?
Lexeo Therapeutics’s EPS for 12 months was -$1.26.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process